The global Cell Therapy and Gene Therapy CDMO market size is predicted to grow from US$ 5067 million in 2025 to US$ 15700 million in 2031; it is expected to grow at a CAGR of 20.7% from 2025 to 2031.
Cell and Gene Therapy (CGT for short, excluding broad cell therapies such as unmodified stem cells) is a method of using gene therapy vectors to transduce exogenous therapeutic genes into cells, and then through external Transcription and translation of source genes, a method of changing the original gene expression of cells to treat diseases.
United States market for Cell Therapy and Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Cell Therapy and Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Cell Therapy and Gene Therapy CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Cell Therapy and Gene Therapy CDMO players cover Lonza Pharmaceuticals, Thermo Fisher, catalent, Jubilant LifeSciences, Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淐ell Therapy and Gene Therapy CDMO Industry Forecast鈥� looks at past sales and reviews total world Cell Therapy and Gene Therapy CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Cell Therapy and Gene Therapy CDMO sales for 2025 through 2031. With Cell Therapy and Gene Therapy CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Therapy and Gene Therapy CDMO industry.
This Insight Report provides a comprehensive analysis of the global Cell Therapy and Gene Therapy CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Therapy and Gene Therapy CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cell Therapy and Gene Therapy CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Therapy and Gene Therapy CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Therapy and Gene Therapy CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Therapy and Gene Therapy CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cell Therapy
Gene Therapy
Segmentation by Application:
Clinical Stage Projects
Commercialization Stage Projects
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Pharmaceuticals
Thermo Fisher
catalent
Jubilant LifeSciences
Boehringer Ingelheim
Oxford BioMedica
Charles River
WuXi AppTec
He Yuan Biology
GenScript Biotech
Kanglong Chemical
Porton shares
Sano Biologics
Yunzhou Biology
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Cell Therapy and Gene Therapy CDMO 麻豆原创 Size (2020-2031)
2.1.2 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Cell Therapy and Gene Therapy CDMO by Country/Region (2020, 2024 & 2031)
2.2 Cell Therapy and Gene Therapy CDMO Segment by Type
2.2.1 Cell Therapy
2.2.2 Gene Therapy
2.3 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Type
2.3.1 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Cell Therapy and Gene Therapy CDMO 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Cell Therapy and Gene Therapy CDMO Segment by Application
2.4.1 Clinical Stage Projects
2.4.2 Commercialization Stage Projects
2.5 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Application
2.5.1 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Cell Therapy and Gene Therapy CDMO 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Player
3.1 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Cell Therapy and Gene Therapy CDMO Revenue by Player (2020-2025)
3.1.2 Global Cell Therapy and Gene Therapy CDMO Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Cell Therapy and Gene Therapy CDMO Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cell Therapy and Gene Therapy CDMO by Region
4.1 Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Region (2020-2025)
4.2 Global Cell Therapy and Gene Therapy CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cell Therapy and Gene Therapy CDMO 麻豆原创 Size Growth (2020-2025)
4.4 APAC Cell Therapy and Gene Therapy CDMO 麻豆原创 Size Growth (2020-2025)
4.5 Europe Cell Therapy and Gene Therapy CDMO 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Cell Therapy and Gene Therapy CDMO 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Country (2020-2025)
5.2 Americas Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Type (2020-2025)
5.3 Americas Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Region (2020-2025)
6.2 APAC Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Type (2020-2025)
6.3 APAC Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Country (2020-2025)
7.2 Europe Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Type (2020-2025)
7.3 Europe Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cell Therapy and Gene Therapy CDMO by Region (2020-2025)
8.2 Middle East & Africa Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Cell Therapy and Gene Therapy CDMO 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Cell Therapy and Gene Therapy CDMO 麻豆原创 Forecast
10.1 Global Cell Therapy and Gene Therapy CDMO Forecast by Region (2026-2031)
10.1.1 Global Cell Therapy and Gene Therapy CDMO Forecast by Region (2026-2031)
10.1.2 Americas Cell Therapy and Gene Therapy CDMO Forecast
10.1.3 APAC Cell Therapy and Gene Therapy CDMO Forecast
10.1.4 Europe Cell Therapy and Gene Therapy CDMO Forecast
10.1.5 Middle East & Africa Cell Therapy and Gene Therapy CDMO Forecast
10.2 Americas Cell Therapy and Gene Therapy CDMO Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.2.2 Canada 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.2.3 Mexico 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.2.4 Brazil 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.3 APAC Cell Therapy and Gene Therapy CDMO Forecast by Region (2026-2031)
10.3.1 China Cell Therapy and Gene Therapy CDMO 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.3.3 Korea 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.3.4 Southeast Asia 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.3.5 India 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.3.6 Australia 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.4 Europe Cell Therapy and Gene Therapy CDMO Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.4.2 France 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.4.3 UK 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.4.4 Italy 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.4.5 Russia 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.5 Middle East & Africa Cell Therapy and Gene Therapy CDMO Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.5.2 South Africa 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.5.3 Israel 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.5.4 Turkey 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
10.6 Global Cell Therapy and Gene Therapy CDMO Forecast by Type (2026-2031)
10.7 Global Cell Therapy and Gene Therapy CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Cell Therapy and Gene Therapy CDMO Forecast
11 Key Players Analysis
11.1 Lonza Pharmaceuticals
11.1.1 Lonza Pharmaceuticals Company Information
11.1.2 Lonza Pharmaceuticals Cell Therapy and Gene Therapy CDMO Product Offered
11.1.3 Lonza Pharmaceuticals Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Lonza Pharmaceuticals Main Business Overview
11.1.5 Lonza Pharmaceuticals Latest Developments
11.2 Thermo Fisher
11.2.1 Thermo Fisher Company Information
11.2.2 Thermo Fisher Cell Therapy and Gene Therapy CDMO Product Offered
11.2.3 Thermo Fisher Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Thermo Fisher Main Business Overview
11.2.5 Thermo Fisher Latest Developments
11.3 catalent
11.3.1 catalent Company Information
11.3.2 catalent Cell Therapy and Gene Therapy CDMO Product Offered
11.3.3 catalent Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 catalent Main Business Overview
11.3.5 catalent Latest Developments
11.4 Jubilant LifeSciences
11.4.1 Jubilant LifeSciences Company Information
11.4.2 Jubilant LifeSciences Cell Therapy and Gene Therapy CDMO Product Offered
11.4.3 Jubilant LifeSciences Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Jubilant LifeSciences Main Business Overview
11.4.5 Jubilant LifeSciences Latest Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Information
11.5.2 Boehringer Ingelheim Cell Therapy and Gene Therapy CDMO Product Offered
11.5.3 Boehringer Ingelheim Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Boehringer Ingelheim Main Business Overview
11.5.5 Boehringer Ingelheim Latest Developments
11.6 Oxford BioMedica
11.6.1 Oxford BioMedica Company Information
11.6.2 Oxford BioMedica Cell Therapy and Gene Therapy CDMO Product Offered
11.6.3 Oxford BioMedica Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Oxford BioMedica Main Business Overview
11.6.5 Oxford BioMedica Latest Developments
11.7 Charles River
11.7.1 Charles River Company Information
11.7.2 Charles River Cell Therapy and Gene Therapy CDMO Product Offered
11.7.3 Charles River Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Charles River Main Business Overview
11.7.5 Charles River Latest Developments
11.8 WuXi AppTec
11.8.1 WuXi AppTec Company Information
11.8.2 WuXi AppTec Cell Therapy and Gene Therapy CDMO Product Offered
11.8.3 WuXi AppTec Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 WuXi AppTec Main Business Overview
11.8.5 WuXi AppTec Latest Developments
11.9 He Yuan Biology
11.9.1 He Yuan Biology Company Information
11.9.2 He Yuan Biology Cell Therapy and Gene Therapy CDMO Product Offered
11.9.3 He Yuan Biology Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 He Yuan Biology Main Business Overview
11.9.5 He Yuan Biology Latest Developments
11.10 GenScript Biotech
11.10.1 GenScript Biotech Company Information
11.10.2 GenScript Biotech Cell Therapy and Gene Therapy CDMO Product Offered
11.10.3 GenScript Biotech Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 GenScript Biotech Main Business Overview
11.10.5 GenScript Biotech Latest Developments
11.11 Kanglong Chemical
11.11.1 Kanglong Chemical Company Information
11.11.2 Kanglong Chemical Cell Therapy and Gene Therapy CDMO Product Offered
11.11.3 Kanglong Chemical Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Kanglong Chemical Main Business Overview
11.11.5 Kanglong Chemical Latest Developments
11.12 Porton shares
11.12.1 Porton shares Company Information
11.12.2 Porton shares Cell Therapy and Gene Therapy CDMO Product Offered
11.12.3 Porton shares Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Porton shares Main Business Overview
11.12.5 Porton shares Latest Developments
11.13 Sano Biologics
11.13.1 Sano Biologics Company Information
11.13.2 Sano Biologics Cell Therapy and Gene Therapy CDMO Product Offered
11.13.3 Sano Biologics Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Sano Biologics Main Business Overview
11.13.5 Sano Biologics Latest Developments
11.14 Yunzhou Biology
11.14.1 Yunzhou Biology Company Information
11.14.2 Yunzhou Biology Cell Therapy and Gene Therapy CDMO Product Offered
11.14.3 Yunzhou Biology Cell Therapy and Gene Therapy CDMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Yunzhou Biology Main Business Overview
11.14.5 Yunzhou Biology Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
